{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:28:31Z","timestamp":1785803311034,"version":"3.56.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001249","name":"University of Tasmania","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001249","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    It is still unclear whether hypertensive patients using angiotensin II receptor blockers (ARBs) have a different risk of developing dementia compared with those taking angiotensin-converting enzyme inhibitors (ACEIs). We conducted a prospective cohort study using the 45 and Up Study Cohort in patients aged\u2009\u2265\u200945\u00a0years with hypertension who initiated ARB or ACEI therapy between 2004 and June 30, 2022. ARB\/ACEI exposure was defined as having a supply that covered at least 80% of their follow-up period. Propensity score matching was used to balance baseline characteristics. We used the Cox proportional hazards model to estimate the risk of incident dementia. We included 51,574 patients with hypertension (mean age 66.3 (9.0) years; 48.2% women), with a mean follow-up of 11.3 (5.2) years. After controlling for major modifiable lifestyle factors such as diet and physical activity, ARB use was linked to a significantly reduced risk of dementia compared with ACEI use (hazard ratio [HR]\u2009=\u20090.72; 95% confidence interval [CI]: 0.65\u20130.80,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). In exploratory agent-level analyses, compared with lisinopril, olmesartan (HR\u2009=\u20090.32; 95% CI: 0.16\u20130.62), candesartan (HR\u2009=\u20090.41; 95% CI: 0.24\u20130.69), telmisartan (HR\u2009=\u20090.42; 95% CI: 0.25\u20130.71), irbesartan (HR\u2009=\u20090.45; 95% CI: 0.27\u20130.75), and perindopril (HR\u2009=\u20090.52; 95% CI: 0.31\u20130.87) were associated with a significantly lower risk of dementia, while captopril showed a significantly increased risk (HR\u2009=\u20094.9; 95% CI: 1.04\u201323.4). The findings were consistent across subgroup analyses (sex, head-to-head ARBs vs ACEIs) and sensitivity analyses (excluding hypertension defined only by antihypertensive medication use, adjusting for competing risk of death or inverse probability of treatment weighting analysis). Among hypertensive patients, ARB use was linked to a reduced risk of dementia compared with ACEI treatment, regardless of diet and physical activity, and the effect varied across specific agents. These findings highlight the potential role of ARBs in dementia prevention; however, further randomised controlled trials are needed to confirm them.\n                  <\/jats:p>","DOI":"10.1007\/s11357-026-02173-3","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T21:59:38Z","timestamp":1772229578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term risk of dementia with angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors in hypertensive patients: A 15-year follow-up using the 45 and Up Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0421-4327","authenticated-orcid":false,"given":"Eyayaw Ashete","family":"Belachew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S.","family":"Salahudeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woldesellassie M.","family":"Bezabhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2173_CR1","unstructured":"World Health Organization. Dementia Key Facts 2020, Geneva, WHO, [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia]."},{"key":"2173_CR2","unstructured":"Dementia prevalence to double without urgent commitment to brain health [Internet]. 2025. Available from: https:\/\/www.dementia.org.au\/media-centre\/media-releases\/dementia-prevalence-double-without-urgent-commitment-brain-health."},{"issue":"4","key":"2173_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1161\/ATVBAHA.118.311906","volume":"39","author":"AY Fouda","year":"2019","unstructured":"Fouda AY, Fagan SC, Ergul A. Brain vasculature and cognition. Arterioscler Thromb Vasc Biol. 2019;39(4):593\u2013602.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2173_CR4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI158453","author":"MM Gonzales","year":"2022","unstructured":"Gonzales MM, Garbarino VR, Pollet E, Palavicini JP, Kellogg DL Jr., Kraig E, et al. Biological aging processes underlying cognitive decline and neurodegenerative disease. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI158453.","journal-title":"J Clin Invest"},{"key":"2173_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.843305","volume":"14","author":"R Watanabe","year":"2022","unstructured":"Watanabe R, Hashimoto M. Aging-related vascular inflammation: giant cell arteritis and neurological disorders. Front Aging Neurosci. 2022;14:843305.","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"2173_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41440-024-01622-w","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Okura A, Hoshide S, Mogi M. The WHO global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res. 2024;47(5):1099\u2013102.","journal-title":"Hypertens Res"},{"issue":"10248","key":"2173_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413\u201346.","journal-title":"Lancet"},{"key":"2173_CR8","doi-asserted-by":"publisher","unstructured":"National Academies of Sciences, Engineering, and Medicine. Preventing cognitive decline and dementia: a way forward. Leshner AI, Landis S, Stroud C, Downey A, editors. Washington (DC): The National Academies Press; 2017. p. 180.\u00a0https:\/\/doi.org\/10.17226\/24782.","DOI":"10.17226\/24782"},{"issue":"1","key":"2173_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1474-4422(19)30393-X","volume":"19","author":"J Ding","year":"2020","unstructured":"Ding J, Davis-Plourde KL, Sedaghat S, Tully PJ, Wang W, Phillips C, et al. Antihypertensive medications and risk for incident dementia and Alzheimer\u2019s disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol. 2020;19(1):61\u201370.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2173_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1474-4422(10)70250-7","volume":"10","author":"C Anderson","year":"2011","unstructured":"Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011;10(1):43\u201353.","journal-title":"Lancet Neurol"},{"key":"2173_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaf121","author":"ECL Cheung","year":"2025","unstructured":"Cheung ECL, Adesuyan M, Szilcz M, Kalisch Ellett LM, Shah S, Jani YH, et al. Antihypertensive drug classes and risk of incident dementia: a multinational population-based cohort study. Age Ageing. 2025. https:\/\/doi.org\/10.1093\/ageing\/afaf121.","journal-title":"Age Ageing"},{"key":"2173_CR12","doi-asserted-by":"publisher","unstructured":"Derington CG, Berchie RO, Scharfstein DO, Andrews RM, Greene TH, Xu Y, King JB, Supiano MA, Sonnen JA, Williamson J, Pajewski NM, Pruzin JJ, Cohen JB, Bress AP. Effect of initiation and continuous adherence to ARBs versus ACEIs on risk of adjudicated mild cognitive impairment or dementia. J Gerontol A Biol Sci Med Sci. 2025;80(7):glaf028. https:\/\/doi.org\/10.1093\/gerona\/glaf028.","DOI":"10.1093\/gerona\/glaf028"},{"key":"2173_CR13","doi-asserted-by":"publisher","first-page":"105378","DOI":"10.1016\/j.ebiom.2024.105378","volume":"109","author":"SK Lundin","year":"2024","unstructured":"Lundin SK, Hu X, Feng J, Lundin KK, Li L, Chen Y, et al. Association between risk of Alzheimer\u2019s disease and related dementias and angiotensin receptor \u2161 blockers treatment for individuals with hypertension in high-volume claims data. EBioMedicine. 2024;109:105378.","journal-title":"EBioMedicine"},{"issue":"1","key":"2173_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.49370","volume":"6","author":"ZA Marcum","year":"2023","unstructured":"Marcum ZA, Gabriel N, Bress AP, Hernandez I. Association of new use of antihypertensives that stimulate vs inhibit type 2 and 4 angiotensin II receptors with dementia among medicare beneficiaries. JAMA Netw Open. 2023;6(1):e2249370.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2173_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100028","volume":"12","author":"AN Vidyanti","year":"2025","unstructured":"Vidyanti AN, Rahmawati F, Rahman RH, Prodjohardjono A, Gofir A. Lifestyle interventions for dementia risk reduction: a review on the role of physical activity and diet in Western and Asian Countries. J Prev Alzheimers Dis. 2025;12(2):100028.","journal-title":"J Prev Alzheimers Dis"},{"key":"2173_CR16","unstructured":"Sax Institute. The Chronic Conditions Umbrella Program Linkage (CUPL) Factsheet. Sydney: Sax Institute; 2023. Available from: https:\/\/www.saxinstitute.org.au\/solutions\/45-and-up-study\/use-the-45-and-up-study\/cupl\/."},{"issue":"1","key":"2173_CR17","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1093\/ije\/dyac104","volume":"52","author":"K Bleicher","year":"2023","unstructured":"Bleicher K, Summerhayes R, Baynes S, Swarbrick M, Navin Cristina T, Luc H, et al. Cohort profile update: the 45 and Up Study. Int J Epidemiol. 2023;52(1):e92\u2013101.","journal-title":"Int J Epidemiol"},{"issue":"2","key":"2173_CR18","doi-asserted-by":"publisher","DOI":"10.17061\/phrp3322317","volume":"33","author":"S Nepal","year":"2023","unstructured":"Nepal S, Dolja-Gore X, Cavenagh D, D\u2019Este C, Anstey KJ, Brodaty H, et al. Addressing dementia through analysis of population traits and risk factors (ADAPTOR) project: dementia incidence in an Australian cohort. Public Health Res Pract. 2023;33(2):e3322317.","journal-title":"Public Health Res Pract"},{"key":"2173_CR19","unstructured":"NSW Ministry of Health. NSW mental health ambulatory data collection (MHAMB). Sydney: NSW Ministry of Health, System Information and Analytics Branch; 2001\u20132023. Unpublished administrative data."},{"key":"2173_CR20","unstructured":"NSW Ministry of Health. NSW admitted patient data collection (APDC). Sydney: NSW Ministry of Health, System Information and Analytics Branch; 2001\u20132023. Unpublished administrative data."},{"key":"2173_CR21","unstructured":"NSW Ministry of Health. NSW emergency department data collection (EDDC). Sydney: NSW Ministry of Health, System Information and Analytics Branch; 2005\u20132023. Unpublished administrative data."},{"key":"2173_CR22","unstructured":"World Health Organization Expert Committee. The selection and use of essential medicines. World Health Organ Tech Rep Ser. 2009;(958):1\u2013242."},{"key":"2173_CR23","unstructured":"Australian Medicines Handbook Pty Ltd. Australian medicines handbook 2024. Adelaide (SA): Australian Medicines Handbook Pty Ltd; 2024."},{"key":"2173_CR24","first-page":"25","volume":"6","author":"DP Nau","year":"2012","unstructured":"Nau DP. Proportion of days covered (PDC) as a preferred method of measuring medication adherence. Springfield, VA: Pharmacy Quality Alliance. 2012;6:25.","journal-title":"Springfield, VA: Pharmacy Quality Alliance"},{"issue":"7-8","key":"2173_CR25","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1345\/aph.1H018","volume":"40","author":"LM Hess","year":"2006","unstructured":"Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7\u20138):1280\u20138.","journal-title":"Ann Pharmacother"},{"issue":"9","key":"2173_CR26","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1080\/03007995.2018.1477747","volume":"34","author":"CA Forbes","year":"2018","unstructured":"Forbes CA, Deshpande S, Sorio-Vilela F, Kutikova L, Duffy S, Gouni-Berthold I, et al. A systematic literature review comparing methods for the measurement of patient persistence and adherence. Curr Med Res Opin. 2018;34(9):1613\u201325.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"2173_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40256-019-00371-3","volume":"20","author":"I Hernandez","year":"2020","unstructured":"Hernandez I, He M, Brooks MM, Saba S, Gellad WF. Adherence to anticoagulation and risk of stroke among medicare beneficiaries newly diagnosed with atrial fibrillation. Am J Cardiovasc Drugs. 2020;20(2):199\u2013207.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"2173_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1177\/13872877251362202","volume":"107","author":"T Vu","year":"2025","unstructured":"Vu T, Almeida OP, Flicker L, Waller M, Wolfe R, Ryan J, et al. Validation of multiple linked administrative datasets to identify people with dementia. J Alzheimers Dis. 2025;107(2):671\u201381.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2173_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65273-w","volume":"10","author":"HJ Welberry","year":"2020","unstructured":"Welberry HJ, Brodaty H, Hsu B, Barbieri S, Jorm LR. Measuring dementia incidence within a cohort of 267,153 older Australians using routinely collected linked administrative data. Sci Rep. 2020;10(1):8781.","journal-title":"Sci Rep"},{"issue":"8","key":"2173_CR30","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jalz.2018.02.016","volume":"14","author":"T Wilkinson","year":"2018","unstructured":"Wilkinson T, Ly A, Schnier C, Rannikm\u00e4e K, Bush K, Brayne C, et al. Identifying dementia cases with routinely collected health data: a\u00a0systematic review. Alzheimers Dement. 2018;14(8):1038\u201351.","journal-title":"Alzheimers Dement"},{"key":"2173_CR31","doi-asserted-by":"publisher","first-page":"100927","DOI":"10.1016\/j.lanepe.2024.100927","volume":"42","author":"JL Schroevers","year":"2024","unstructured":"Schroevers JL, Hoevenaar-Blom MP, Busschers WB, Hollander M, Van Gool WA, Richard E, et al. Antihypertensive medication classes and risk of incident dementia in primary care patients: a longitudinal cohort study in the Netherlands. Lancet Reg Health Eur. 2024;42:100927.","journal-title":"Lancet Reg Health Eur"},{"key":"2173_CR32","doi-asserted-by":"crossref","unstructured":"van Dalen JW, Marcum ZA, Gray SL, Barthold D, Moll van Charante EP, van Gool WA, et al. Association of angiotensin II-stimulating antihypertensive use and dementia risk: post hoc analysis of the PreDIVA Trial. Neurology. 2021;96(1):e67\u2013e80.","DOI":"10.1212\/WNL.0000000000010996"},{"issue":"8","key":"2173_CR33","first-page":"656","volume":"13","author":"CG Lyketsos","year":"2005","unstructured":"Lyketsos CG, Toone L, Tschanz J, Rabins PV, Steinberg M, Onyike CU, et al. Population-based study of medical comorbidity in early dementia and \u201ccognitive impairment, no dementia (CIND)\u201d: association with functional and cognitive impairment: the Cache County Study. Am J Geriatr Psychiatry. 2005;13(8):656\u201364.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"2173_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","volume":"4","author":"M Boustani","year":"2008","unstructured":"Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311\u201320.","journal-title":"Aging Health"},{"key":"2173_CR35","unstructured":"Australian Institute of Health and Welfare. The active Australia survey: a guide and manual for implementation, analysis and reporting. Canberra (ACT): Australian Institute of Health and Welfare; 2003. https:\/\/www.aihw.gov.au\/reports\/physical-activity\/active-australia-survey-manual."},{"key":"2173_CR36","unstructured":"Organization WH. Global recommendations on physical activity for health. Geneva: WHO Press. https:\/\/www.who.int\/publications\/i\/item\/9789241599979. 2010."},{"key":"2173_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ypmed.2016.12.044","volume":"97","author":"S Mihrshahi","year":"2017","unstructured":"Mihrshahi S, Ding D, Gale J, Allman-Farinelli M, Banks E, Bauman AE. Vegetarian diet and all-cause mortality: evidence from a large population-based Australian cohort - the 45 and up study. Prev Med. 2017;97:1\u20137.","journal-title":"Prev Med"},{"issue":"25","key":"2173_CR38","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"issue":"1","key":"2173_CR39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","volume":"69","author":"D Schoenfeld","year":"1982","unstructured":"Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239\u201341.","journal-title":"Biometrika"},{"key":"2173_CR40","doi-asserted-by":"publisher","first-page":"m441","DOI":"10.1136\/bmj.m441","volume":"368","author":"RD Riley","year":"2020","unstructured":"Riley RD, Ensor J, Snell KIE, Harrell FE Jr, Martin GP, Reitsma JB, et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;368:m441.","journal-title":"BMJ"},{"key":"2173_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b5465","volume":"340","author":"NC Li","year":"2010","unstructured":"Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465.","journal-title":"BMJ"},{"issue":"6","key":"2173_CR42","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.18632\/aging.205589","volume":"16","author":"S Hao","year":"2024","unstructured":"Hao S, He Q, Yuan Y, Mu Q. The protective effects of Irbesartan in cognitive impairment in hypertension. Aging (Albany NY). 2024;16(6):5065\u201376.","journal-title":"Aging (Albany NY)"},{"issue":"11","key":"2173_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206705","volume":"13","author":"D Barthold","year":"2018","unstructured":"Barthold D, Joyce G, Wharton W, Kehoe P, Zissimopoulos J. The association of multiple anti-hypertensive medication classes with Alzheimer\u2019s disease incidence across sex, race, and ethnicity. PLoS ONE. 2018;13(11):e0206705.","journal-title":"PLoS ONE"},{"issue":"446","key":"2173_CR44","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496\u2013509.","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"2173_CR45","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1097\/HJH.0000000000000086","volume":"32","author":"W-C Chiu","year":"2014","unstructured":"Chiu W-C, Ho W-C, Lin M-H, Lee H-H, Yeh Y-C, Wang J-D, et al. Angiotension receptor blockers reduce the risk of dementia. J Hypertens. 2014;32(4):938\u201347.","journal-title":"J Hypertens"},{"issue":"10","key":"2173_CR46","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1161\/HYPERTENSIONAHA.122.19378","volume":"79","author":"Z Deng","year":"2022","unstructured":"Deng Z, Jiang J, Wang J, Pan D, Zhu Y, Li H, et al. Angiotensin receptor blockers are associated with a lower risk of progression from mild cognitive impairment to dementia. Hypertension. 2022;79(10):2159\u201369.","journal-title":"Hypertension"},{"issue":"9","key":"2173_CR47","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamaneurol.2015.1001","volume":"72","author":"I Hajjar","year":"2015","unstructured":"Hajjar I, Levey A. Association between angiotensin receptor blockers and longitudinal decline in tau in mild cognitive impairment. JAMA Neurol. 2015;72(9):1069\u201370.","journal-title":"JAMA Neurol"},{"issue":"7","key":"2173_CR48","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1161\/01.CIR.0000138848.58269.80","volume":"110","author":"M Iwai","year":"2004","unstructured":"Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation. 2004;110(7):843\u20138.","journal-title":"Circulation"},{"issue":"6","key":"2173_CR49","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/labinvest.2011.45","volume":"91","author":"Y Maejima","year":"2011","unstructured":"Maejima Y, Okada H, Haraguchi G, Onai Y, Kosuge H, Suzuki J-i, et al. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest. 2011;91(6):932\u201344.","journal-title":"Lab Invest"},{"issue":"17","key":"2173_CR50","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","volume":"109","author":"M Schupp","year":"2004","unstructured":"Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator\u2013activated receptor-\u03b3 activity. Circulation. 2004;109(17):2054\u20137.","journal-title":"Circulation"},{"issue":"45","key":"2173_CR51","doi-asserted-by":"publisher","first-page":"37644","DOI":"10.1074\/jbc.M508460200","volume":"280","author":"ML Hemming","year":"2005","unstructured":"Hemming ML, Selkoe DJ. Amyloid \u03b2-protein is degraded by cellular Angiotensin-converting Enzyme (ACE) and elevated by an ACE Inhibitor*. J Biol Chem. 2005;280(45):37644\u201350.","journal-title":"J Biol Chem"},{"key":"2173_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00221","volume":"6","author":"X Sun","year":"2015","unstructured":"Sun X, Chen WD, Wang YD. \u03b2-amyloid: the key peptide in the pathogenesis of Alzheimer\u2019s disease. Front Pharmacol. 2015;6:221.","journal-title":"Front Pharmacol"},{"issue":"5","key":"2173_CR53","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507\u201320.","journal-title":"JAMA"},{"issue":"4","key":"2173_CR54","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2007","unstructured":"Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2007;167(4):492\u20139.","journal-title":"Am J Epidemiol"},{"issue":"19","key":"2173_CR55","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127\u2013248.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"2173_CR56","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.2020.4249","volume":"323","author":"D Hughes","year":"2020","unstructured":"Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley W, et al. Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA. 2020;323(19):1934\u201344.","journal-title":"JAMA"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-026-02173-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-026-02173-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-026-02173-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T23:02:42Z","timestamp":1772233362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-026-02173-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":56,"alternative-id":["2173"],"URL":"https:\/\/doi.org\/10.1007\/s11357-026-02173-3","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The conduct of the 45 and Up Study was approved by the University of NSW Human Research Ethics Committee. Ethical approval for this study was granted by the NSW Population & Health Services Research Ethics Committee (Reference Number: 2021\/ETH12383) following review and approval by the Sax Institute Scientific Review Panel. Project access was authorised by the Sax Institute, with data availability commencing in March 2025. Researchers accessed the data securely through the Sax Institute\u2019s Secure Unified Research Environment (SURE). All datasets were de-identified before analysis, with participant-level linkage across databases enabled using unique Sax Institute Project Person Numbers (PPN). All participants provided consent for ongoing follow-up and linkage to routinely collected health data using participant PPN.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}